In confirmation, Rivory et al. demonstrated that, in advanced cancer patients, the ones with acute phase response (CRP > 10 mg/L) presented a 30% lower CYP3A metabolic activity with respect to patients without acute phase response. Here, CYP3A4 is linked to cancer.